FDA Confirms Accelerated Approval Pathway for ProKidney's Rilparencel, Q2 2027 Data Targeted
PROK has more than doubled off its 52-week low of $0.46 on light trading volume (0.4× avg).
Summary
ProKidney reported full-year 2025 financial results and significant business highlights, most notably confirming with the FDA that eGFR slope from the ongoing Phase 3 PROACT 1 study can serve as the surrogate endpoint for accelerated approval of rilparencel. This regulatory clarity significantly de-risks the company's lead asset and provides a faster path to market, with pivotal eGFR slope data anticipated in Q2 2027 and BLA submission in Q4 2027. The company also reported positive Phase 2 REGEN-007 study results and strong enrollment momentum in the Phase 3 PROACT 1 study. Financially, ProKidney ended 2025 with $270.0 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into mid-2027. Investors will be watching for completion of Phase 3 enrollment in mid-2026 and the critical Q2 2027 data readout.
At the time of this announcement, PROK was trading at $2.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $625.7M. The 52-week trading range was $0.46 to $7.13. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.